Health Catalyst, Inc. (HCAT) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.45
↓-73% vs avg
5yr avg: 1.65
30Y Low0.7·High6.2
ROE
↓
-58.3%
↑-67% vs avg
5yr avg: -34.9%
30Y Low-58%·High-19%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HCAT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Health Catalyst, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $111M | $167M | $426M | $522M | $575M | $1.9B | $1.7B | $650M | — | — |
| Enterprise Value | $80M | $136M | $578M | $665M | $707M | $1.9B | $1.8B | $685M | — | — |
| P/E Ratio → | -0.62 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.36 | 0.54 | 1.39 | 1.77 | 2.08 | 7.78 | 9.11 | 4.20 | — | — |
| P/B Ratio | 0.45 | 0.68 | 1.17 | 1.42 | 1.35 | 3.60 | 6.23 | 3.24 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | 152.49 | 228.52 | 29.23 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
HCAT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.44 | 1.89 | 2.25 | 2.56 | 7.83 | 9.66 | 4.42 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
HCAT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Health Catalyst, Inc. earns an operating margin of -51.7%. Operating margins have compressed from -42.9% to -51.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -58.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 48.7% | 48.7% | 45.9% | 44.5% | 48.2% | 48.6% | 48.1% | 51.4% | 46.8% | 40.3% |
| Operating Margin | -51.7% | -51.7% | -22.8% | -42.9% | -50.7% | -59.4% | -50.9% | -35.4% | -53.4% | -62.3% |
| Net Profit Margin | -57.2% | -57.2% | -22.7% | -39.9% | -49.7% | -63.3% | -60.9% | -38.8% | -55.1% | -64.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.3% | -58.3% | -19.0% | -29.8% | -29.0% | -38.4% | -48.3% | -30.0% | — | — |
| ROA | -26.1% | -26.1% | -8.9% | -16.3% | -17.3% | -21.7% | -26.1% | -29.1% | -56.0% | -42.7% |
| ROIC | -32.9% | -32.9% | -10.2% | -17.8% | -19.3% | -23.6% | -23.5% | -17.5% | — | — |
| ROCE | -34.0% | -34.0% | -12.2% | -19.8% | -19.9% | -23.4% | -25.8% | -33.9% | -80.8% | -57.3% |
HCAT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $51M exceeds total debt of $20M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 1.10 | 0.68 | 0.58 | 0.39 | 0.71 | 0.26 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.13 | 0.42 | 0.39 | 0.31 | 0.02 | 0.37 | 0.17 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -4.09 | -17.41 | -19.34 | -8.30 | -7.01 | -8.76 | -23.23 | -22.69 |
Net cash position: cash ($51M) exceeds total debt ($20M)
HCAT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.89x means Health Catalyst, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 4.42x to 1.89x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | 1.89 | 1.43 | 4.42 | 5.18 | 5.46 | 3.75 | 5.48 | 1.60 | 2.32 |
| Quick Ratio | 1.89 | 1.89 | 1.43 | 4.42 | 5.18 | 5.46 | 3.75 | 5.48 | 1.60 | 2.32 |
| Cash Ratio | 1.07 | 1.07 | 1.20 | 3.57 | 4.41 | 4.78 | 3.08 | 4.73 | 0.79 | 1.67 |
| Asset Turnover | — | 0.62 | 0.36 | 0.42 | 0.37 | 0.29 | 0.33 | 0.51 | 1.01 | 0.66 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 69.36 | 68.08 | 74.36 | 63.38 | 73.63 | 93.35 | 64.95 | 89.80 | 85.17 |
HCAT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Health Catalyst, Inc. returns 4.5% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 4.5% | 3.0% | 0.0% | 0.3% | 1.5% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 4.5% | 3.0% | 0.0% | 0.3% | 1.5% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $70M | $60M | $56M | $54M | $47M | $40M | $19M | $28M | $28M |
Peer Comparison
Compare HCAT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HCATYou | $111M | -0.6 | — | — | 48.7% | -51.7% | -58.3% | -32.9% | — |
 HIMS | $7B | 52.7 | 44.5 | 93.8 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 DOCS | $5B | 23.1 | 20.8 | 19.4 | 90.2% | 39.9% | 22.5% | 20.0% | 0.1 |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 TDOC | $1B | -6.0 | 14.8 | 4.3 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 PINC | $2B | 128.5 | 21.3 | 7.3 | 73.4% | 0.1% | 1.2% | 0.0% | 2.4 |
 MSFT | $3.1T | 30.3 | 19.4 | 42.9 | 68.8% | 45.6% | 33.3% | 24.9% | 0.7 |
 ORCL | $558B | 44.7 | 27.3 | — | 70.5% | 30.8% | 82.4% | 12.8% | 4.4 |
 CRM | $174B | 23.2 | 19.5 | 12.1 | 77.7% | 21.5% | 12.4% | 10.9% | 0.8 |
 AMZN | $3.0T | 38.3 | 20.7 | 384.3 | 50.3% | 11.2% | 22.3% | 14.7% | 1.0 |
 GOOG | $4.8T | 36.5 | 32.0 | 65.2 | 59.7% | 32.1% | 35.7% | 25.1% | 0.4 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See HCAT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HCAT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HCAT vs HIMS
Side-by-side business, growth, and profitability comparison vs Hims & Hers Health, Inc..
Start ComparisonHCAT — Frequently Asked Questions
Quick answers to the most common questions about buying HCAT stock.
What is Health Catalyst, Inc.'s P/E ratio?
Health Catalyst, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
What is Health Catalyst, Inc.'s ROE?
Health Catalyst, Inc.'s return on equity (ROE) is -58.3%. The historical average is -36.1%.
Is HCAT stock overvalued?
Based on historical data, Health Catalyst, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Health Catalyst, Inc.'s profit margins?
Health Catalyst, Inc. has 48.7% gross margin and -51.7% operating margin.